Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 8/20 | 0.33 |
| ▸ | BCHE | P06276 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 5/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021685 | 0.92 | EPHX2 (0.41) | EPHX2ACHEBCHECHRM2CHRM1 | |
| SCHEMBL22021680 | 0.92 | EPHX2 (0.41) | EPHX2ACHEBCHECHRM2CHRM1 | |
| SCHEMBL22021658 | 0.92 | EPHX2 (0.41) | EPHX2ACHEBCHECHRM2CHRM1 | |
| SCHEMBL22021683 | 0.87 | NAMPT (0.32) | EPHX2CNR1NAMPT | |
| SCHEMBL22021691 | 0.86 | EPHX2 (0.50) | EPHX2CNR1ALDH1A1KDM4CKDM5A | |
| SCHEMBL21456131 | 0.85 | CYP4F2 (0.42) | EPHX2CNR1ACHEBCHECHRM2 | |
| SCHEMBL22166531 | 0.85 | EPHX2 (0.53) | EPHX2CNR1ALDH1A1KDM4CKDM5A | |
| SCHEMBL22166535 | 0.85 | EPHX2 (0.53) | EPHX2CNR1ALDH1A1KDM4CKDM5A | |
| SCHEMBL22021900 | 0.84 | EPHX2 (0.36) | EPHX2ACHEBCHECHRM2CHRM1 | |
| SCHEMBL23639725 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220220124-A1 | NOVEL COMPOUNDS HAVING BET, ESTROGEN RECEPTOR, AND ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-11117885-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117885-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | EPHX2 896/4885CNR1 645/4885ALDH1A1 430/4885 |
| US-20220220124-A1 | NOVEL COMPOUNDS HAVING BET, ESTROGEN RECEPTOR, AND ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, ESRRA, ESR1 | EPHX2 2088/4885CNR1 151/4885ALDH1A1 568/4885 |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | EPHX2 951/4885CNR1 495/4885ALDH1A1 350/4885 |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | EPHX2 896/4885CNR1 645/4885ALDH1A1 430/4885 |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | CDK3, CDK4, CDK1 | EPHX2 1763/4885CNR1 844/4885ALDH1A1 4096/4885 |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | EPHX2 896/4885CNR1 645/4885ALDH1A1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.